CXCR4 and lymphoma: Coinjection of 2 mg/kg AMD3100 (Fig. 3, white bars) resulted in a reduction of tumor uptake by 88% (1.5 h p.i.), demonstrating the high CXCR4-specificity of [64Cu]NOTA-pentixather accumulation in the lymphoma xenograft.